Summary
In a clinical phase-II study fludarabine phosphate was given to 20 patients with advanced chronic lymphocytic leukemia who had failed on prior conventional therapy. Fludarabine was administered at a dose of 25 mg/m2/d for 5 days. Treatment cycles were repeated every 4 weeks until maximal response, followed by two cycles for consolidation. Four of the 20 patients achieved complete remission and seven patients partial remission, resulting in an overall response rate of 55% (11/20). Fludarabine therapy was well tolerated, with mild myelosuppression and secondary infections comprising the predominant side effects. These data warrant further confirmation and a randomized comparison of fludarabine with established regimens, which is currently underway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Avramis VI (1989) Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphat (F-araAMP) in P 388 murine leukemia-bearing mice. Cancer Invest 7: 129–137
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tehernia G, Jacquillat C, Biovin Lesty C, Duault MT, Monoconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198–201
Binet JL, Catovsky D, Chandra P, Dighiero G, Montserrat E, Rai KR, Sawitsky A (1981) Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Br J Haematol 48: 365–367
Brockman RW, Schabel FM jr, Montgomery JA (1977) Biologic activity of 9-beta-D-arabino-furanosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabino-furanosyl adenine. Biochem Pharmacol 26: 2193–2196
Brockman RW, Cheng YC, Schabel FM jr, Montgomery JA (1980) Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L 1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40: 3610–3615
Chun HG, Leyland-Jones B, Cheson BD (1991) Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 9: 175–188
Cutler SJ, Young JL (1975) Third National Cancer Survey: incidence data. Natl Cancer Inst Monogr 41
French Cooperative Group on Chronic Lymphocytic Leukaemia (1986) Effectiveness of “CHOP” regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1: 1346–1349
Grever MR, Coltman CA, Files JC, Greenberg BR, Hutton JJ, Talley RL, von Hoff DD, Balcerzak SP (1986) Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 68: 223 a
Idestrom K, Kimby E, Bjorkholm M, Mellstedt H, Engstedt L, Gahrton G, Johansson B, Killander D, Roberts KH, Stalfelt AM, Uden AM, Wadman B, Wahlby S (1982) Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous lowor intermittent high-dose prednismustine versus chlorambucil/prednisolone. Eur J Cancer 18: 1117–1123
Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ (1990) Fludarabine therapy in macroglobulinemic lymphoma. Blood 75: 1928–1931
Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19–25
Keating MJ, Kantarjian H, O'Brian S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9: 44–49
Keller JW, Knospe WH, Raney M, Huguley CM, Johnson L, Bartolucci AA, Omura GA (1986) Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy: Southeastern Cancer Study Group. Cancer 58: 1185–1192
Leiby JA, Snider KM, Kraut EH, Metz EN, Malspeis L, Grever MR (1987) Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47: 2719–2722
Merkel DE, Griffin NL, Kagan-Hallet K, von Hoff DD (1986) Central nervous system toxicity with fludarabine. Cancer Treat Rep 70: 1449–1450
Montserrat E, Alcala A, Paraody R, Domingo A, Garcia-Conde J, Bueno J, Ferran C, Sanz MA, Giralt M, Rubio D, Anton I, Estape J, Rozman C (1985) Treatment of chronic lymphocytic leukemia in advanced stages: a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 56: 2369–2375
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234
Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F jr, Rodriguez MA, Plunkett WK, Keating MJ (1991) Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol (in press)
Sawitsky A, Rai KR, Glidewell O, Silver RT (1977) Cancer and Leukemia Group B: comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50: 1049–1059
Warrell RP, Berman E (1986) Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4: 74–79
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. Dr. G. Schellong on the occasion of his 65th birthday
Rights and permissions
About this article
Cite this article
Hiddemann, W., Rottmann, R., Wörmann, B. et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Ann Hematol 63, 1–4 (1991). https://doi.org/10.1007/BF01714952
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01714952